Torrent Pharmaceuticals revenue and financials
₹4,680.20Change from previous close: −1.92%Absolute change: −₹91.80
In the fiscal year ended March 2026, Torrent Pharmaceuticals reported revenue of ₹137.53B (+21.52% year over year). Net income was ₹21.63B, a net margin of 15.7%.
Fiscal year ending in March. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +21.52%
- FY to Mar 2026 vs FY to Mar 2025
- Net income growth
- +13.19%
- FY to Mar 2026 vs FY to Mar 2025
- Net margin
- 15.7%
- FY to Mar 2025: 16.9%
Financial data
Amounts in millions of INR; per-share values in INR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Total revenue | 48,350 | 41,280 | 32,510 | 32,460 | 31,280 | — |
| Cost of revenue | 11,630 | 10,150 | 7,990 | 8,000 | 7,740 | — |
| Gross profit | 36,720 | 31,130 | 24,520 | 24,460 | 23,540 | — |
| Operating income | 10,710 | 8,480 | 8,820 | 8,790 | 8,310 | — |
| EBIT | 10,380 | 7,650 | 8,590 | 8,390 | 7,940 | — |
| EBITDA | 16,310 | 12,730 | 10,650 | 10,430 | 9,950 | — |
| Interest expense | 3,050 | 2,360 | 450 | 480 | 560 | — |
| Pre-tax income | 7,330 | 5,290 | 8,140 | 7,910 | 7,380 | — |
| Income tax | 1,670 | 1,650 | 1,790 | 2,000 | 1,900 | — |
| Net income | 5,660 | 3,890 | 6,350 | 5,910 | 5,480 | — |
| Net income to common shareholders | 5,660 | 3,890 | 6,350 | 5,910 | 5,480 | — |
| Basic EPS | 14.87 | 11.51 | 18.77 | 17.45 | 16.19 | — |
| Diluted EPS | 14.87 | 11.51 | 18.77 | 17.45 | 16.19 | — |
| Average shares (basic) | 381 | 338 | 338 | 339 | 338 | — |
| Average shares (diluted) | 381 | 338 | 338 | 339 | 338 | — |